Cancer Biomarkers

Cancer Biomarkers : Minimal and Noninvasive Early Diagnosis and Prognosis

Edited by  , Edited by  , Edited by  , Edited by 

Free delivery worldwide

Available. Dispatched from the UK in 3 business days
When will my order arrive?


Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume The book details the general and technical aspects of noninvasive cancer markers.It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis * Presents noninvasive early molecular markers in urological cancers * Describes gynecological and endocrine cancer markers * Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers * Addresses hematological malignancies * Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin's lymphoma, and multiple myeloma * Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker more

Product details

  • Hardback | 951 pages
  • 182 x 258 x 62mm | 2,039.97g
  • Taylor & Francis Inc
  • CRC Press Inc
  • Bosa Roca, United States
  • English
  • 128 black & white illustrations, 145 black & white tables
  • 1466584289
  • 9781466584280
  • 2,293,204

About Debmalya Barh

Debmalya Barh (MSc, MTech, MPhil, PhD, PGDM) is the founder and president of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. He is a consultant biotechnologist and an active researcher in integrative omics-based biomarkers, targeted drug discovery, and personalized medicine in cancer, neurodisorders, and cardiovascular, infectious, and metabolic diseases. He works with nearly 400 esteemed researchers from 30-35 countries and he has more than 100 high-impact publications. He has edited ten books in the field of omics. He also serves as an editorial and review board member for several highly respected international journals. Dr. Angelo Carpi is a clinical professor of medicine at the Pisa University Medical School, Pisa, Italy. He received his MD and postgraduate diplomas in internal medicine and nuclear medicine from the University of Pisa and his diploma of qualification on peptide hormones from the Collegio Medico Giuridico-Scuola Normale Superiore and the Scuola Superiore Sant'Anna, Pisa, Italy. His clinical practice and research included thyroid and breast tumors. He has authored about 300 publications included in PubMed. He is a member of the editorial boards of international journals such as Biomedicine & Pharmacotherapy and Frontiers in Bioscience. Dr. Mukesh Verma is a program director and chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Verma received his MSc from Pantnagar University and his PhD from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 128 research articles, book chapters, and reviews, and has edited three books in the field of cancer epigenetics and epidemiology. Mehmet Gunduz, MD, PhD, is a professor of otolaryngology and medical genetics, Faculty of Medicine, Turgut Ozal University, Turkey. He graduated from Medical School Hacettepe University in 1990, and completed his residency in otolaryngology at the same university. He received his PhD from Okayama University and Wakayama Medical University, Japan, and is medical board certified from both the Turkish and Japanese certification authorities. One of the pioneers in identifying ING family tumor suppressors, Dr. Gunduz has contributed to more than 150 international publications, 3,000 citations, several book chapters, and over 200 presentations in national and international more

Table of contents

Part I General and Technical Aspects Quality Control and Ethical Issues of Cancer Biomarker Discovery Anjana Munshi and Vandana Sharma Imaging Techniques in Cancer Diagnosis Mohamed Abd El-Salam, Sonia Reda, Salwa Lotfi, Tamar Refaat, and Eman El-Abd Role of PET in Cancer Diagnosis Silvia Taralli, Antonella Stefanelli, and Giorgio Treglia Innovative Tools for Early Detection of Cancer Ali Tiss, Amal Hasan, Abdelkrim Khadir, Mohammed Dehbi, and Said Dermime Noninvasive Nanodiagnostics for Cancer Sandhiya Selvarajan, Melvin George, and Suresh Kumar Mitochondrial DNA in Early Cancer Diagnosis and Screening Mukesh Verma, Neelesh Agarwal, and Mudit Verma Circulating miRNA Biomarkers in Various Solid Cancers Martina Redova, Hana Mlcochova, and Ondrej Slaby Stem Cell Biomarkers in Early Diagnosis, Prognosis, and Therapy of Cancer Dipali Dhawan and Harish Padh Salivary Biomarkers in Early Diagnosis and Monitoring of Cancer Saroj K Basak and Eri S Srivatsan Part II Brain and Head and Neck Cancers Biomarkers for Brain Gliomas Yusuf Izci Noninvasive Biomarkers in Head and Neck Squamous Cell Carcinoma Anand Kumar, Mumtaz Ahmad Ansari, and Vivek Srivastava Biological Markers in Oral Squamous Cell Carcinoma Mario Perez-Sayans Garcia, Danielle Resende Camisasca, Abel Garcia Garcia, Simone de Queiroz Chaves Lourenco, and Anastasios Markopoulos Part III Gastrointestinal Cancers Biomarkers for Gastric Cancer and the Related Premalignant Conditions Marcis Leja, Jan Bornschein, Juozas Kupcinskas, and Peter Malfertheiner Biomarkers in Esophageal Adenocarcinoma Simon JW Monkhouse, J Muhlschlegel, and H Barr Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma Dengfu Yao, Min Yao, Xiaodi Yan, Li Wang, and Zhizhen Dong Noninvasive Early Markers in Gallbladder Cancer Mumtaz Ahmad Ansari, Ruhi Dixit, and Vijay Kumar Shukla Noninvasive Early Markers in Pancreatic Cancer Aleksandra Nikolic Part IV Lung Cancer and Mesothelioma Noninvasive Early Markers in Lung Cancer Mukesh Verma, Debmalya Barh, and Neha Jain Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers in Lung Cancer: Bridging the Gap from Bench to Bedside Meggie Hakim, Ulrike Tisch, Michael Unger, and Hossam Haick Part V Urological Cancers Noninvasive Early Molecular Biomarkers in Kidney Cancer Brian W Cross, Jonathan Huang, and Viraj A Master Novel Oncomarkers Used for Earlier Detection of Bladder Carcinoma Miroslava Bilecova-Rabajdova, Peter Urban, Maria Marekova, and Vincent Nagy Screening for Prostate Cancer: New Markers and Future Aspects Nigel P Murray Part VI Gynecological and Endocrine Cancers Early Biomarkers in Breast Cancer Ruchika Kaul-Ghanekar, Snehal Suryavanshi, and Prerna Raina Noninvasive Biomarkers in Ovarian Cancer Sharon A O'Toole, Eugen Ancuta, Ream Langhe, Dolores J Cahill, Mairead Murphy, Cara Martin, Lynda McEvoy, Cathy Spillane, Orla Sheils, Emmanuel Petricoin, Lance Liotta, and John J O'Leary Early Markers for Neoplastic Lesions of the Uterine Cervix Pablo Conesa-Zamora Biomarkers in Diagnosis of Papillary Thyroid Carcinoma Marisa Canadas-Garre, Nuria Munoz Perez, Jesus Maria Villar del Moral, Jose Antonio Ferron Orihuela, and Jose Manuel Llamas-Elvira Biomolecular Markers for Improving Management of Follicular and Medullary Thyroid Cancer Umut Mousa, Cuneyd Anil, Serife Mehlika Isildak, Alptekin Gursoy, and Angelo Carpi Part VII Hematological Cancers Biomarkers in Myelodysplastic Syndrome Nestor L Lopez Corrales and Vasco Ariston de Carvalho Azevedo Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia Ota Fuchs Biomarkers in Hodgkin's Lymphoma Esin Demir, Burak Yilmaz, Mehmet Gunduz, and Esra Gunduz Multiple Myeloma and Evolution of Novel Biomarkers and Therapies Michael Byrne, Joseph Katz, and Jan S Moreb Part VIII Melanoma Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma Eijun Itakura and Alistair J Cochran Indexshow more

Review quote

"This book gathers a unique collection of information on cancer biomarkers that will be an invaluable reference for those in the field. It is particularly commendable for its extensive use of tables listing biomarkers, their clinical applications, and the state of clinical validation each has received. By bringing this information together into a single book, the authors provide essential background for the formulation of new diagnostic approaches to individual cancer types not available elsewhere. Weighted numerical score: 81 - 3 stars." -Steven Smith, Ph.D, City of Hope, Duarte, California, USA, from Doody's Book Reviewsshow more